EHA: Adding Pirtobrutinib to Venetoclax-Rituximab Ups PFS in Chronic Lymphocytic Leukemia

Pytobrutinib is a non-covalent (reversible) BTK (Brutton's tyrosine kinase) inhibitor. It is the first and only non-covalent BTK inhibitor approved by the FDA, with a unique mechanism of action and excellent therapeutic effects.

Veneclare is a prescription drug that targets the BCL-2 protein. It was approved for marketing in the United States in April 2016. It should be used only as directed by a doctor.

Venetoclax is a world-first selective drug that targets the B-cell lymphoma-2 (BCL-2) protein. BCL-2 plays a crucial role in certain blood cancers or other cancers, preventing cancer cell death (apoptosis). Venetoclax works by blocking the BCL-2 protein, thus restoring the apoptosis process. Venetoclax aims to selectively inhibit BCL-2 function, restore cellular communication systems, and induce cancer cell self-destruction, thereby achieving the goal of treating tumors.